Heart HealthSemaglutide May Prevent Heart Valve Calcification Driven by Kidney Disease
Chronic kidney disease dramatically raises the risk of calcific aortic valve disease, but why has remained unclear. This study used UK Biobank population data, single-cell RNA sequencing of human heart valves, and genetic analyses to pinpoint a critical molecular pathway. Researchers found that SIRT1 — a longevity-associated enzyme — is sharply reduced in valve cells from CKD patients, triggering inflammation, cellular aging, and calcium buildup via the NF-κB/NLRP3 inflammasome axis. Blocking NLRP3 reduced calcification in animal models. Remarkably, semaglutide — widely known as a diabetes and weight-loss drug — restored the SIRT1/NLRP3 balance and reduced valve calcification in both cell and animal experiments, suggesting a potential repurposing opportunity for this already-approved drug.
